

Atrial Fibrillation

Bibliography of One Hundred Key Papers

selected by **A. John Camm, MD; Irina Savelieva, MD**

Department of Cardiological Sciences - St George's Hospital Medical School - Cranmer Terrace
London SW1 0RE - UK (e-mail: jcamm@sghms.ac.uk)

Allessie MA, Bonke FI, Schopman FJ.	<i>Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The leading circle concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle.</i> Circ Res. 1977;41:9-18.
Allessie MA, Boyden PA, Camm AJ, et al.	<i>Pathophysiology and prevention of atrial fibrillation.</i> Circulation. 2001;103:769-777.
Al-Saady N, Obel OA, Camm AJ.	<i>Left atrial appendage: structure, function, and role in thromboembolism.</i> Heart. 1999;82:547-555.
Andersen HR, Nielsen JC, Thomsen PEB, et al.	<i>Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick sinus syndrome.</i> Lancet. 1997;350:1210-1216.
Atrial Fibrillation Investigators.	<i>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials.</i> Arch Intern Med. 1994;154:1449-1457.
Atrial Fibrillation Investigators.	<i>Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1,066 patients from three clinical trials.</i> Arch Intern Med. 1998;158:1316-1320.
Ausma J, Van Der Velden HMW, Lenders MH, et al.	<i>Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat.</i> Circulation. 2003;107:2051-2058.
Becker R, Klinkott R, Bauer A, et al.	<i>Multisite pacing for prevention of atrial tachyarrhythmias: potential mechanisms.</i> J Am Coll Cardiol. 2000;35:1939-1946.
Benditt DG, Williams JH, Jin J, et al, for the d,l-Sotalol Atrial Fibrillation/Flutter Study Group.	<i>Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter.</i> Am J Cardiol. 1999;84:270-277.
Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.	<i>Impact of atrial fibrillation on risk of death: the Framingham Study.</i> Circulation. 1999;98:946-952.
Boriani G, Biffi M, Capucci A, et al.	<i>Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.</i> PACE. 1998;21:2470-2474.
Brugada R, Tapscott T, Czernuszewicz GZ, et al.	<i>Identification of a genetic locus for familial atrial fibrillation.</i> N Engl J Med. 1997;336:905-911.

Bibliography of One Hundred Key Papers

- Camm AJ.** *Atrial fibrillation: is there a role for low-molecular-weight heparin?*
Clin Cardiol. 2001;24:115-119.
-
- Camm AJ, Evans KE, Ward DE, Martin A.** *The rhythm of the heart in active elderly subjects.*
Am J Cardiol. 1980;99:598-603.
-
- Camm AJ, Savelieva I.** *Rate versus rhythm control: is the debate over?*
J Interv Card Electrophysiol. 2002;7:7-11.
-
- Camm AJ, Savelieva I.** *Rationale and patient selection for "Hybrid" drug and device therapy in atrial and ventricular arrhythmias.*
J Interv Card Electrophysiol. 2003;9:207-214.
-
- Carlsson J, Tebbe U, Rox J, et al, for the ALKK Study Group.** *Cardioversion of atrial fibrillation in the elderly.*
Am J Cardiol. 1996;78:1380-1384.
-
- Capucci A, Villani GO, Piepoli MF, Aschieri D.** *The role of oral IC antiarrhythmic drugs in terminating atrial fibrillation.*
Curr Opin Cardiol. 1999;14:4-8.
-
- Connolly SJ.** *Evidence-based analysis of amiodarone efficacy and safety.*
Circulation. 1999;100:2025-2034.
-
- Connolly SJ, Schnell DJ, Page RL, et al.** *Dose-response relations of azimilide in the management of symptomatic, recurrent atrial fibrillation.*
Am J Cardiol. 2001;88:974-979.
-
- Crijns HJGM, Tjeerdsma G, De Kam PJ, et al.** *Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure.*
Eur Heart J. 2000;21:1238-1245.
-
- D'Allonnes GR, Pavin D, Leclercq C, et al.** *Long-term effects of biatrial synchronous pacing to prevent drug-refractory atrial tachyarrhythmia: a nine-year experience.*
J Cardiovasc Electrophysiol. 2000;11:1081-1091.
-
- Deedwania PC, Singh BN, Ellenbogen K, for the Department of Veterans Affairs CHF-STAT Investigators.** *Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT).*
Circulation. 1998;98:2574-2579.
-
- Defaye P, Dournaux F, Mouton E, for the AIDA Multicenter Study Group.** *Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study.*
Stem Cells. 2001;19:304-312.
-
- De Simone A, Stabile G, Vitale DF, et al.** *Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.*
J Am Coll Cardiol. 1999;34:810-814.
-
- Dorian P, Jung W, Newman D, et al.** *The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy.*
J Am Coll Cardiol. 2000;36:1303-1309.
-
- Dries DL, Exner DV, Gersh BJ, et al.** *Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials.*
J Am Coll Cardiol. 1998;32:695-703.
-



-
- Evans W, Swann P.** *Lone auricular fibrillation.*
Am Heart J. 1953;189-194.
-
- Ezekowitz MD, James KE, Nazarian SM, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.** *Silent cerebral infarction in patients with nonrheumatic atrial fibrillation.*
Circulation. 1995;92:2178-2182.
-
- Farshi R, Kistner D, Sarma JSM, et al.** *Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover, open-label study of five drug regimens.*
J Am Coll Cardiol. 1998;22:304-310.
-
- Friedman PA, Dijkman B, Warman EN, et al, for the Worldwide Jewel AF Investigators.** *Atrial therapies reduce atrial arrhythmia burden in defibrillator patients.*
Circulation. 2001;104:1023-1028.
-
- Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, for the CHS Collaborative Research Group.** *Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).*
Am J Cardiol. 1994;74:236-241.
-
- Fuster V, Rydén LE, Asinger RV, et al.** *Task Force Report: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation.*
Eur Heart J. 2001;22:1852-1923.
-
- Glotzer TY, Hellkamp AS, Zimmerman J, et al, for the MOST Investigators.** *Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST).*
Circulation. 2003;107:1614-1619.
-
- Go AS, Hylek EM, Phillips KA, et al.** *Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTi-coagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study.*
JAMA. 2001;285:2370-2375.
-
- Gottdiener JS, Arnold AM, Aurigemma GP, et al.** *Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.*
J Am Coll Cardiol. 2000;35:1628-1637.
-
- Haisaguerre M, Jais P, Shah DC, et al.** *Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.*
N Engl J Med. 1998;339:659-666.
-
- Haissaguerre M, Jais P, Shah DC, et al.** *Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci.*
Circulation. 2000;101:1409-1417.
-
- Hart RG, Benavente O, McBride R, Pearce LA.** *Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.*
Ann Intern Med. 1999;131:492-501.
-
- Hart RG, Pearce LA, McBride R, et al.** *Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.*
Stroke. 1999;30:1223-1229.
-

Bibliography of One Hundred Key Papers

-
- Hart RG, Pearce LA, Rothbart RM, et al.** *Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy.*
J Am Coll Cardiol. 2000;35:183-187.
-
- Hernandez-Madrid A, Bueno MG, Rebollo JG, et al.** *Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.*
Circulation. 2002;39:106:331-336.
-
- Jorgensen HS, Nakayama H, Reith J, et al.** *Acute stroke with atrial fibrillation: the Copenhagen Stroke Study.*
Stroke. 1996;27:1765-1769.
-
- Jouven X, Desnos M, Guerot C, Ducimetiere P.** *Idiopathic atrial fibrillation as a risk for mortality: the Paris Prospective Study I.*
Eur Heart J. 1999;20:896-899.
-
- Kamath S, Blann AD, Lip GYH.** *Platelets and atrial fibrillation.*
Eur Heart J. 2001;22:2233-2242.
-
- Kannel WB, Abbott RD, Savage DD, McNamara PM.** *Epidemiologic features of chronic atrial fibrillation: the Framingham Study.*
N Engl J Med. 1982;306:1018-1022.
-
- Kay GN, Bubien RS, Epstein AE, Plumb VJ.** *Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance.*
Am J Cardiol. 1988;62:741-744.
-
- Klein AL, Grimm RA, Murray RD, et al, for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators.** *Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.*
N Engl J Med. 2001;344:1411-1420.
-
- Kopecky SL, Gersh BJ, McGoon MD, et al.** *The natural history of lone atrial fibrillation: a population-based study over three decades.*
N Engl J Med. 1987;317:669-674.
-
- Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE.** *The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study.*
Am J Med. 1995;98:476-484.
-
- Lamas GA, Lee KL, Sweeney MO, et al, for the Mode Selection Trial in Sinus-Node Dysfunction.** *Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.*
N Engl J Med. 2002;346:1854-1862.
-
- Lee SH, Chen SA, Tai CT, et al.** *Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation.*
J Am Coll Cardiol. 1998;31:637-644.
-
- Levy S, Maarek M, Coumel P, et al, on behalf of the College of French Cardiologists.** *Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA Study.*
Circulation. 1999;99:3028-3035.
-
- Levy S, Richard P, Lau CP, et al.** *Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation.*
J Am Coll Cardiol. 1997;27:750-755.
-
- Lewis T.** *Auricular fibrillation and its relationship to clinical irregularity of the heart.*
Heart. 1910;1:306-372.
-



-
- Lewis T, Schleiter HG.** *The relation of regular tachycardias of auricular origin to auricular fibrillation.*
Heart. 1912;3:173-193.
-
- Lown B.** *Electrical reversion of cardiac arrhythmias. Thomas Lewis Lecture.*
Br Heart J. 1967;29:469-489.
-
- Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM.** *Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.*
JAMA. 1999;281:610-655.
-
- Maron BJ, Olivotto I, Bellone P, et al.** *Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.*
J Am Coll Cardiol. 2002;39:301-307.
-
- Martin A, Benbow LJ, Butrous GS, Leach C, Camm AJ.** *Five year follow-up of 101 elderly subjects by means of long-term ambulatory cardiac monitoring.*
Eur Heart J. 1984;5:592-596.
-
- Mathew J, Hunsberger S, Fleg J, et al, for the Digitalis Investigation Group.** *Incidence, predictive factors, and prognostic significance of supra-ventricular tachyarrhythmias in congestive heart failure.*
Chest. 2000;118:914-922.
-
- Members of the Sicilian Gambit.** *New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias.*
Eur Heart J. 2001;22:2148-2163.
-
- Moe GK, Abildskov JA.** *Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge.*
Am Heart J. 1959;58:59-70.
-
- Moe GK, Rheinholdt WC, Abildskov JA.** *A computer model of atrial fibrillation.*
Am Heart J. 1964;67:200-220.
-
- Naccarelli GV, Dorian P, Hohnloser S, Coumel P, for the Flecainide Multicenter Atrial Fibrillation Study Group.** *Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter.*
Am J Cardiol. 1996;77:53A-59A.
-
- Ozcan C, Jahangir A, Friedman PA, et al.** *Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation.*
N Engl J Med. 2001;344:1043-1051.
-
- Pappone C, Rosanio S, Oreto G, et al.** *Circumferential radiofrequency ablation of pulmonary vein ostia.*
Circulation. 2000;102:2619-2628.
-
- Pedersen OD, Bagger H, Keller N, et al, for the Danish Investigations of Arrhythmia and Mortality ON Dofetilide Study Group.** *Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Substudy.*
Circulation. 2001;104:292-296.
-
- Pederson OD, Bagger H, Køber L, et al, for the TRACE Study Group.** *Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.*
Circulation. 1999;100:376-380.
-
- Pritchett ELC, Page RL, Connolly SJ, et al.** *Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response.*
J Am Coll Cardiol. 2000;36:794-802.
-

Bibliography of One Hundred Key Papers

- Psaty BM, Manolio TA, Kuller LH, et al.** *Incidence of and risk factors for atrial fibrillation in older adults.* **Circulation.** 1997;96:2455-2461.
-
- Ravelli F, Allessie M.** *Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart.* **Circulation.** 1997;96:1686-1695.
-
- Rawles JM.** *What is meant by a "controlled" ventricular rate in atrial fibrillation?* **Br Heart J.** 1990;63:157-161.
-
- Roy D, Talajic M, Dorian P, et al, for the Canadian Trial of Atrial Fibrillation Investigators.** *Amiodarone to prevent recurrence of atrial fibrillation.* **N Engl J Med.** 2000;342:913-920.
-
- Saksena S, Giorgberidze I, Mehra R, et al.** *Electrophysiology and endocardial mapping of induced atrial fibrillation in patients with spontaneous atrial fibrillation.* **Am J Cardiol.** 1999;83:187-193.
-
- Saksena S, Prakash A, Ziegler P, et al, for the DAPPAF Investigators.** *The Dual-site Atrial Pacing for Prevention of Atrial Fibrillation (DAPPAF) trial: improved suppression of atrial fibrillation with dual-site atrial pacing and antiarrhythmic drug therapy.* **J Am Coll Cardiol.** 2001;38:598-599.
-
- Savelieva I, Camm AJ.** *Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.* **J Interv Card Electrophysiol.** 2000;4:369-382.
-
- Savelieva I, Camm AJ.** *The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?* **J Interv Card Electrophysiol.** 2003;8:103-115.
-
- Singh S, Zoble RG, Yellen L, et al, for the Dofetilide Atrial Fibrillation Investigators.** *Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study.* **Circulation.** 2000;102:2385-2390.
-
- Skanes AC, Krahn AD, Yee R, et al, for the CTOPP Investigators.** *Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing.* **J Am Coll Cardiol.** 2001;38:167-172.
-
- Slavik RS, Tisdale JE, Borzak S.** *Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.* **Prog Cardiovasc Dis.** 2001;44:121-152.
-
- Sohara H, Amitani S, Kurose M, Miyahara K.** *Atrial fibrillation activates platelets and coagulation in a time dependent manner: a study in patients with paroxysmal atrial fibrillation.* **J Am Coll Cardiol.** 1997;29:106-112.
-
- Stabile G, De Simone A, Turco P, et al.** *Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation.* **J Am Coll Cardiol.** 2001;37:1639-1644.
-
- Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG.** *Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.* **Chest.** 2001;119:220S-227S.
-



-
- Stewart S, MacIntyre K, MacLeod MMC, et al.** *Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996.*
Eur Heart J. 2001;22:693-701.
-
- Stroobandt R, Stiels B, Hoebrechts R, on behalf of the Propafenone Atrial Fibrillation Trial Investigators.** *Propafenone for conversion and prophylaxis of atrial fibrillation.*
Am J Cardiol. 1997;79:418-423.
-
- The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators.** *A comparison of rate control and rhythm control in patients with atrial fibrillation.*
N Engl J Med. 2002;347:1825-1833.
-
- The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.** *Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation.*
Ann Intern Med. 1998;128:639-647.
-
- Tieleman RG, Van Gelder IC, Crijns HJGM, et al.** *Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria.*
J Am Coll Cardiol. 1998;31:167-173.
-
- Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al, for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.** *Dofetilide in patients with congestive heart failure and left ventricular dysfunction.*
N Engl J Med. 1999;341:857-865.
-
- UK Propafenone PSVT Study Group.** *A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation.*
Circulation. 1995;92:2550-2557.
-
- Van Gelder IC, Crijns HJCM, Tieleman RG, et al.** *Value and limitation of electrical cardioversion in patients with chronic atrial fibrillation: importance of arrhythmia risk factors and oral anticoagulation.*
Arch Intern Med. 1996;156:2585-2592.
-
- Van Gelder IC, Hagens VE, Bosker HA, et al, for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group.** *A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.*
N Engl J Med. 2002;347:1834-1840.
-
- Van Walraven C, Hart R, Singer D, et al.** *Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: an individual patient meta-analysis.*
JAMA. 2002;288:2441-2448.
-
- Volgman AS, Carberry PA, Stambler B, et al.** *Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.*
J Am Coll Cardiol. 1998;31:1414-1419.
-
- Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA.** *Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis.*
Circulation. 2000;101:1138-1144.
-
- Wellens HJJ, Lau CP, Lüderitz B, et al.** *Atrioverter: an implantable device for the treatment of atrial fibrillation.*
Circulation. 1998;98:1651-1656.
-

Bibliography of One Hundred Key Papers

Wijffels MCEF, Kirchhoff CJHJ, Dorland R, et al.

Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation.
Circulation. 1997;96:3710-3720.

Wolf PA, Abbott RD, Kannel WB.

Atrial fibrillation: a major contributor to stroke in the elderly.
Arch Intern Med. 1987;147:1561-1564.

Wolf PA, Abbott RD, Kannel WB.

Atrial fibrillation as independent risk factor for stroke: the Framingham Study.
Stroke. 1991;22:983-988.

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in **English**. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), short running title, keywords, and acknowledgments, as well as full names (first name, middle name(s), and last name) with highest academic degrees (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—hard copies and on disk, where possible) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All illustrations should be cited in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Systeme International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and numbered consecutively using superscript arabic numerals. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the bibliography, titles of journals should be abbreviated according to the Index Medicus. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals “the Vancouver style.* Ann Intern Med. 1997;126:36-47). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg.* 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation.* 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza.* Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting:** all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial dept according to the specifications of the current edition of the **American Medical Association Manual of Style, Williams & Wilkins**. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial dept will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial dept and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.

- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

EDITORIAL

The editorial should not exceed 2 standard typed pages (maximum 600 words).

LEAD ARTICLE

The lead article should not exceed 25 standard typed pages (maximum 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of **10 references of “seminal papers”** as well as a separate list of **100 Key References** should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 25 standard typed pages (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.